Article

Colleagues mourn, celebrate pioneer Judah Folkman, MD

Judah Folkman, MD, whose work in cancer research led to significant breakthroughs in treating age-related macular degeneration, is being remembered as the kindly and compassionate "father of angiogenesis."

Key Points

The founder and director of the vascular biology program at Children's Hospital Boston died suddenly Jan. 14 after apparently having a heart attack at the Denver International Airport while en route to speak at a conference in Vancouver, British Columbia. He was 74 years old.

Those in the field of ophthalmology hailed Dr. Folkman for this discovery and follow-up work that led to the development of drugs on the market that are helping to preserve sight in patients around the world. When he delivered the keynote address at the American Academy of Ophthalmology annual meeting in November, ophthalmologists commended him with a standing ovation (see related article "Ophthalmology plays crucial role in angiogenesis research, Dr. Folkman says").

Early interest

From an early age, Dr. Folkman had a keen interest in science and was driven to find solutions that would aid patients.

Born Moses Judah Folkman in Cleveland in 1933 and the son of a rabbi, Dr. Folkman has been quoted as saying that he knew as a child that he wanted to become a doctor so that he could help suffering people. He first attended Ohio State University, then was accepted into Harvard Medical School at age 19. There, he helped develop the world's first implantable heart pacemaker. It serves as a model for today's devices.

As a researcher for the U.S. Navy in the early 1960s, Dr. Folkman began testing his theory that tumors require blood vessels to grow. To do this, he injected small tumors into the avascular cornea, about 2.5 mm from the limbus, said Henry Brem, MD, director of neurosurgery, the Harvey Cushing Professor of Neurosurgery, and professor of oncology and ophthalmology, Johns Hopkins University.

In that way, Dr. Folkman demonstrated that he was able to stimulate blood vessel growth in the eye, show how blood vessels grow, and how- if they were treated with inhibitors-their growth could be blocked, said Dr. Brem. He worked in Dr. Folkman's laboratory in 1973 and was one of several colleagues who provided insights into the man to Ophthalmology Times.

Dr. Folkman's landmark paper was published in 1971 in the New England Journal of Medicine. It hypothesized that tumors require a blood supply to nourish them, but that if that supply could be stopped, then the tumors would die. At that time, the lab employed about 10 people-compared with about 125 today. Dr. Folkman was the youngest full professor in Harvard Medical School's history, and he became its youngest department chairman.

From 1973 to 1974, young Dr. Brem served as a liaison between Dr. Folkman and the Baltimore lab of Arnall Patz, MD, who had become famous for his work on retinopathy of prematurity. Through that research with Dr. Patz, Dr. Brem helped Dr. Folkman write some of the first papers linking angiogenesis and ophthalmology.

Even in those early days, his lectures were "standing room only," Dr. Brem said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.